{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T12:51:32Z","timestamp":1789995092081,"version":"4.0.1"},"reference-count":51,"publisher":"American Society of Hematology","issue":"8","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2003,10,15]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>An internal tandem duplication (ITD) of the juxtamembrane (JM) domain of FLT3 (FLT3\/ITD) has been found in 20% of patients with acute myeloid leukemia (AML) and is correlated with leukocytosis and a poor prognosis. Here, we compared the antiapoptotic effects of wild-type FLT3 (WtFLT3) and FLT3\/ITD in terms of the regulation of Bcl-2 family members. In a murine myeloid cell line, 32D, interleukin-3 (IL-3) deprivation induced apoptosis following the down-regulation of Bcl-XL and the dephosphorylation of Bad. However, the expression levels of Bcl-2, Bax, Bak, and Mcl-1 were unchanged. In WtFLT3-transfected 32D (WtFLT3-32D) cells, FLT3 ligand (FL) stimulation did not restore the down-regulation of Bcl-XL but maintained the phosphorylation of Bad. Combined treatment with phosphatidylinositol 3-kinase (PI3K) inhibitor, LY294002, and mitogen-activated protein kinase kinase (MEK) inhibitor, PD98059, dephosphorylated Bad and induced apoptosis in WtFLT3-32D cells stimulated with FL. Induction of nonphosphorylated Bad induced remarkable apoptosis. These findings suggest that the FL stimulation is associated with antiapoptosis through Bad phosphorylation. On the other hand, FLT3\/ITD-transfected 32D (FLT3\/ITD-32D) cells survived in an IL-3\u2013or FL-deprived state. Furthermore, the dephosphorylation of Bad using LY294002 and PD98059 was insufficient for apoptosis, and the down-regulation of Bcl-XL using antisense treatment was needed to induce apoptosis. FLT3 kinase inhibitor, AG1296, alone not only dephosphorylated Bad but also down-regulated Bcl-XL, leading FLT3\/ITD-32D cells into apoptosis. These findings suggest that the antiapoptotic pathways from FLT3\/ITD are more divergent than those from WtFLT3 and may represent targets for drug discovery with the potential of inducing selective cell death of human leukemia cells.<\/jats:p>","DOI":"10.1182\/blood-2002-12-3813","type":"journal-article","created":{"date-parts":[[2003,7,8]],"date-time":"2003-07-08T00:23:14Z","timestamp":1057623794000},"page":"2969-2975","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":69,"title":["Different antiapoptotic pathways between wild-type and mutated FLT3: insights into therapeutic targets in leukemia"],"prefix":"10.1182","volume":"102","author":[{"given":"Yosuke","family":"Minami","sequence":"first","affiliation":[{"name":"From the Department of Hematology, Nagoya University Graduate School of Medicine, Nagoya, Japan; the Department of Infectious Diseases, Nagoya University School of Medicine, Nagoya, Japan; the Second Department of Internal Medicine, Nagoya City University School of Medicine, Nagoya, Japan; and the Department of Medicine, Nagoya National Hospital, Nagoya, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuhito","family":"Yamamoto","sequence":"additional","affiliation":[{"name":"From the Department of Hematology, Nagoya University Graduate School of Medicine, Nagoya, Japan; the Department of Infectious Diseases, Nagoya University School of Medicine, Nagoya, Japan; the Second Department of Internal Medicine, Nagoya City University School of Medicine, Nagoya, Japan; and the Department of Medicine, Nagoya National Hospital, Nagoya, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hitoshi","family":"Kiyoi","sequence":"additional","affiliation":[{"name":"From the Department of Hematology, Nagoya University Graduate School of Medicine, Nagoya, Japan; the Department of Infectious Diseases, Nagoya University School of Medicine, Nagoya, Japan; the Second Department of Internal Medicine, Nagoya City University School of Medicine, Nagoya, Japan; and the Department of Medicine, Nagoya National Hospital, Nagoya, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryuzo","family":"Ueda","sequence":"additional","affiliation":[{"name":"From the Department of Hematology, Nagoya University Graduate School of Medicine, Nagoya, Japan; the Department of Infectious Diseases, Nagoya University School of Medicine, Nagoya, Japan; the Second Department of Internal Medicine, Nagoya City University School of Medicine, Nagoya, Japan; and the Department of Medicine, Nagoya National Hospital, Nagoya, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hidehiko","family":"Saito","sequence":"additional","affiliation":[{"name":"From the Department of Hematology, Nagoya University Graduate School of Medicine, Nagoya, Japan; the Department of Infectious Diseases, Nagoya University School of Medicine, Nagoya, Japan; the Second Department of Internal Medicine, Nagoya City University School of Medicine, Nagoya, Japan; and the Department of Medicine, Nagoya National Hospital, Nagoya, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoki","family":"Naoe","sequence":"additional","affiliation":[{"name":"From the Department of Hematology, Nagoya University Graduate School of Medicine, Nagoya, Japan; the Department of Infectious Diseases, Nagoya University School of Medicine, Nagoya, Japan; the Second Department of Internal Medicine, Nagoya City University School of Medicine, Nagoya, Japan; and the Department of Medicine, Nagoya National Hospital, Nagoya, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"key":"2020021217533507900_REF1","doi-asserted-by":"crossref","unstructured":"Rosnet O, Schiff C, Pebusque MJ, et al. Human FLT3\/FLK2 gene: cDNA cloning and expression in hematopoietic cells. Blood.1993;82: 1110-1119.","DOI":"10.1182\/blood.V82.4.1110.1110"},{"key":"2020021217533507900_REF2","doi-asserted-by":"crossref","unstructured":"Lyman SD, James L, Vanden Bos T, et al. Molecular cloning of a ligand for the flt3\/flk-2 tyrosine kinase receptor: a proliferative factor for primitive hematopoietic cells. Cell.1993;75: 1157-1167.","DOI":"10.1016\/0092-8674(93)90325-K"},{"key":"2020021217533507900_REF3","doi-asserted-by":"crossref","unstructured":"Lavagna-Sevenier C, Marchetto S, Birnbaum D, Rosnet O. FLT3 signaling in hematopoietic cells involves CBL, SHC and an unknown P115 as prominent tyrosine-phosphorylated substrates. Leukemia.1998;12: 301-310.","DOI":"10.1038\/sj.leu.2400921"},{"key":"2020021217533507900_REF4","doi-asserted-by":"crossref","unstructured":"Zhang S, Broxmeyer HE. Flt3 ligand induces tyrosine phosphorylation of gab1 and gab2 and their association with shp-2, grb2, and PI3 kinase. Biochem Biophys Res Commun.2000;277: 195-199.","DOI":"10.1006\/bbrc.2000.3662"},{"key":"2020021217533507900_REF5","doi-asserted-by":"crossref","unstructured":"Zhang S, Fukuda S, Lee Y, et al. Essential role of signal transducer and activator of transcription (Stat)5a but not Stat5b for Flt3-dependent signaling. J Exp Med.2000;192: 719-728.","DOI":"10.1084\/jem.192.5.719"},{"key":"2020021217533507900_REF6","doi-asserted-by":"crossref","unstructured":"Blume-Jensen P, Hunter T. Oncogenic kinase signalling. Nature.2001;411: 355-365.","DOI":"10.1038\/35077225"},{"key":"2020021217533507900_REF7","unstructured":"Nakao M, Yokota S, Iwai T, et al. Internal tandem duplication of the flt3 gene found in acute myeloid leukemia. Leukemia.1996;10: 1911-1918."},{"key":"2020021217533507900_REF8","doi-asserted-by":"crossref","unstructured":"Yokota S, Kiyoi H, Nakao M, et al. Internal tandem duplication of the FLT3 gene is preferentially seen in acute myeloid leukemia and myelodys-plastic syndrome among various hematological malignancies: a study on a large series of patients and cell lines. Leukemia.1997;11: 1605-1609.","DOI":"10.1038\/sj.leu.2400812"},{"key":"2020021217533507900_REF9","unstructured":"Kiyoi H, Naoe T, Nakano Y, et al. Prognostic implication of FLT3 and N-RAS gene mutations in acute myeloid leukemia. Blood.1999;93: 3074-3080."},{"key":"2020021217533507900_REF10","doi-asserted-by":"crossref","unstructured":"Kottaridis PD, Gale RE, Frew ME, et al. The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials. Blood.2001;98: 1752-1759.","DOI":"10.1182\/blood.V98.6.1752"},{"key":"2020021217533507900_REF11","doi-asserted-by":"crossref","unstructured":"Nakano Y, Kiyoi H, Miyawaki S, et al. Molecular evolution of acute myeloid leukaemia in relapse: unstable N-ras and FLT3 genes compared with p53 gene. Br J Haematol.1999;104: 659-664.","DOI":"10.1046\/j.1365-2141.1999.01256.x"},{"key":"2020021217533507900_REF12","unstructured":"Whitman SP, Archer KJ, Feng L, et al. Absence of the wild-type allele predicts poor prognosis in adult de novo acute myeloid leukemia with normal cytogenetics and the internal tandem duplication of FLT3: a cancer and leukemia group B study. Cancer Res.2001;61: 7233-7239."},{"key":"2020021217533507900_REF13","doi-asserted-by":"crossref","unstructured":"Kiyoi H, Towatari M, Yokota S, et al. Internal tandem duplication of the FLT3 gene is a novel modality of elongation mutation which causes constitutive activation of the product. Leukemia.1998; 12: 1333-1337.","DOI":"10.1038\/sj.leu.2401130"},{"key":"2020021217533507900_REF14","doi-asserted-by":"crossref","unstructured":"Kiyoi H, Ohno R, Ueda R, Saito H, Naoe T. Mechanism of constitutive activation of FLT3 with internal tandem duplication in the juxtamembrane domain. Oncogene.2002;21: 2555-2563.","DOI":"10.1038\/sj.onc.1205332"},{"key":"2020021217533507900_REF15","doi-asserted-by":"crossref","unstructured":"Hayakawa F, Towatari M, Kiyoi H, et al. Tandem-duplicated Flt3 constitutively activates STAT5 and MAP kinase and introduces autonomous cell growth in IL-3-dependent cell lines. Oncogene.2000;19: 624-631.","DOI":"10.1038\/sj.onc.1203354"},{"key":"2020021217533507900_REF16","doi-asserted-by":"crossref","unstructured":"Mizuki M, Fenski R, Halfter H, et al. Flt3 mutations from patients with acute myeloid leukemia induce transformation of 32D cells mediated by the Ras and STAT5 pathways. Blood.2000;96: 3907-3914.","DOI":"10.1182\/blood.V96.12.3907"},{"key":"2020021217533507900_REF17","doi-asserted-by":"crossref","unstructured":"Schimmer AD, Hedley DW, Penn LZ, Minden MD. Receptor- and mitochondrial-mediated apoptosis in acute leukemia: a translational view. Blood.2001;98: 3541-3553.","DOI":"10.1182\/blood.V98.13.3541"},{"key":"2020021217533507900_REF18","doi-asserted-by":"crossref","unstructured":"Cory S, Adams JM. The bcl2 family: regulators of the cellular life-or-death switch. Nat Rev Cancer.2002;2: 647-656.","DOI":"10.1038\/nrc883"},{"key":"2020021217533507900_REF19","doi-asserted-by":"crossref","unstructured":"Veis DJ, Sorenson CM, Shutter JR, Korsmeyer SJ. Bcl-2-deficient mice demonstrate fulminant lymphoid apoptosis, polycystic kidneys, and hypopigmented hair. Cell.1993;75: 229-240.","DOI":"10.1016\/0092-8674(93)80065-M"},{"key":"2020021217533507900_REF20","doi-asserted-by":"crossref","unstructured":"Motoyama N, Wang F, Roth KA, et al. Massive cell death of immature hematopoietic cells and neurons in Bcl-x-deficient mice. Science.1995; 267: 1506-1510.","DOI":"10.1126\/science.7878471"},{"key":"2020021217533507900_REF21","doi-asserted-by":"crossref","unstructured":"Park JR, Bernstein ID, Hockenbery DM. Primitive human hematopoietic precursors express Bcl-x but not Bcl-2. Blood.1995;86: 868-876.","DOI":"10.1182\/blood.V86.3.868.868"},{"key":"2020021217533507900_REF22","doi-asserted-by":"crossref","unstructured":"Dumon S, Santos SC, Debierre-Grockiego F, et al. IL-3 dependent regulation of Bcl-xL gene expression by STAT5 in a bone marrow derived cell line. Oncogene.1999;18: 4191-4199.","DOI":"10.1038\/sj.onc.1202796"},{"key":"2020021217533507900_REF23","doi-asserted-by":"crossref","unstructured":"Zha J, Harada H, Yang E, Jockel J, Korsmeyer SJ. Serine phosphorylation of death agonist BAD in response to survival factor results in binding to 14-3-3 not BCL-XL. Cell.1996;87: 619-628.","DOI":"10.1016\/S0092-8674(00)81382-3"},{"key":"2020021217533507900_REF24","doi-asserted-by":"crossref","unstructured":"Downward J. How BAD phosphorylation is good for survival. Nat Cell Biol.1999;1: E33-E35.","DOI":"10.1038\/10026"},{"key":"2020021217533507900_REF25","doi-asserted-by":"crossref","unstructured":"Bouillet P, Metcalf D, Huang DC, et al. Proapoptotic Bcl-2 relative Bim required for certain apoptotic responses, leukocyte homeostasis, and to preclude autoimmunity. Science.1999;286: 1735-1738.","DOI":"10.1126\/science.286.5445.1735"},{"key":"2020021217533507900_REF26","doi-asserted-by":"crossref","unstructured":"Shinjyo T, Kuribara R, Inukai T, et al. Downregulation of Bim, a proapoptotic relative of Bcl-2, is a pivotal step in cytokine-initiated survival signaling in murine hematopoietic progenitors. Mol Cell Biol.2001;21: 854-864.","DOI":"10.1128\/MCB.21.3.854-864.2001"},{"key":"2020021217533507900_REF27","doi-asserted-by":"crossref","unstructured":"Tse KF, Novelli E, Civin CI, Bohmer FD, Small D. Inhibition of FLT3-mediated transformation by use of a tyrosine kinase inhibitor. Leukemia.2001;15: 1001-1010.","DOI":"10.1038\/sj.leu.2402199"},{"key":"2020021217533507900_REF28","doi-asserted-by":"crossref","unstructured":"Tse KF, Allebach J, Levis M, Smith BD, Bohmer FD, Small D. Inhibition of the transforming activity of FLT3 internal tandem duplication mutants from AML patients by a tyrosine kinase inhibitor. Leukemia.2002;16: 2027-2036.","DOI":"10.1038\/sj.leu.2402674"},{"key":"2020021217533507900_REF29","doi-asserted-by":"crossref","unstructured":"Birkenkamp KU, Esselink MT, Kruijer W, Vellenga E. An inhibitor of PI3-K differentially affects proliferation and IL-6 protein secretion in normal and leukemic myeloid cells depending on the stage of differentiation. Exp Hematol.2000;28: 1239-1249.","DOI":"10.1016\/S0301-472X(00)00529-4"},{"key":"2020021217533507900_REF30","doi-asserted-by":"crossref","unstructured":"Milella M, Kornblau SM, Estrov Z, et al. Therapeutic targeting of the MEK\/MAPK signal transduction module in acute myeloid leukemia. J Clin Invest.2001;108: 851-859.","DOI":"10.1172\/JCI12807"},{"key":"2020021217533507900_REF31","doi-asserted-by":"crossref","unstructured":"Matsuo Y, MacLeod RA, Uphoff CC, et al. Two acute monocytic leukemia (AML-M5a) cell lines (MOLM-13 and MOLM-14) with interclonal phenotypic heterogeneity showing MLL-AF9 fusion resulting from an occult chromosome insertion, ins(11;9)(q23;p22p23). Leukemia.1997;11: 1469-1477.","DOI":"10.1038\/sj.leu.2400768"},{"key":"2020021217533507900_REF32","doi-asserted-by":"crossref","unstructured":"Kitamura K, Yoshida H, Ohno R, Naoe T. Toxic effects of arsenic (As3+) and other metal ions on acute promyelocytic leukemia cells. Int J Hematol.1997;65: 179-185.","DOI":"10.1016\/S0925-5710(96)00547-6"},{"key":"2020021217533507900_REF33","doi-asserted-by":"crossref","unstructured":"Wang K, Yin XM, Chao DT, Milliman CL, Korsmeyer SJ. BID: a novel BH3 domain-only death agonist. Genes Dev.1996;10: 2859-2869.","DOI":"10.1101\/gad.10.22.2859"},{"key":"2020021217533507900_REF34","doi-asserted-by":"crossref","unstructured":"Minami Y, Kiyoi H, Yamamoto Y, et al. Selective apoptosis of tandemly duplicated FLT3-transformed leukemia cells by Hsp90 inhibitors. Leukemia.2002;16: 1535-1540.","DOI":"10.1038\/sj.leu.2402558"},{"key":"2020021217533507900_REF35","doi-asserted-by":"crossref","unstructured":"Wang Z, Karras JG, Howard RG, Rothstein TL. Induction of bcl-x by CD40 engagement rescues sIg-induced apoptosis in murine B cells. J Immunol.1995;155: 3722-3725.","DOI":"10.4049\/jimmunol.155.8.3722"},{"key":"2020021217533507900_REF36","doi-asserted-by":"crossref","unstructured":"Naoe T, Kiyoe H, Yamamoto Y, et al. FLT3 tyrosine kinase as a target molecule for selective antileukemia therapy. Cancer Chemother Pharmacol.2001;48(suppl 1): S27-S30.","DOI":"10.1007\/s002800100301"},{"key":"2020021217533507900_REF37","doi-asserted-by":"crossref","unstructured":"Gilliland DG, Griffin JD. The roles of FLT3 in hematopoiesis and leukemia. Blood.2002;100: 1532-1542.","DOI":"10.1182\/blood-2002-02-0492"},{"key":"2020021217533507900_REF38","doi-asserted-by":"crossref","unstructured":"Nosaka T, Kawashima T, Misawa K, Ikuta K, Mui AL, Kitamura T. STAT5 as a molecular regulator of proliferation, differentiation and apoptosis in hematopoietic cells. Embo J.1999;18: 4754-4765.","DOI":"10.1093\/emboj\/18.17.4754"},{"key":"2020021217533507900_REF39","doi-asserted-by":"crossref","unstructured":"Socolovsky M, Fallon AE, Wang S, Brugnara C, Lodish HF. Fetal anemia and apoptosis of red cell progenitors in Stat5a-\/-5b-\/-mice: a direct role for Stat5 in Bcl-XL induction. Cell.1999;98: 181-191.","DOI":"10.1016\/S0092-8674(00)81013-2"},{"key":"2020021217533507900_REF40","doi-asserted-by":"crossref","unstructured":"Gesbert F, Griffin JD. Bcr\/Abl activates transcription of the Bcl-X gene through STAT5. Blood.2000;96: 2269-2276.","DOI":"10.1182\/blood.V96.6.2269"},{"key":"2020021217533507900_REF41","doi-asserted-by":"crossref","unstructured":"Horita M, Andreu EJ, Benito A, et al. Blockade of the Bcr-Abl kinase activity induces apoptosis of chronic myelogenous leukemia cells by suppressing signal transducer and activator of transcription 5-dependent expression of Bcl-xL. J Exp Med.2000;191: 977-984.","DOI":"10.1084\/jem.191.6.977"},{"key":"2020021217533507900_REF42","doi-asserted-by":"crossref","unstructured":"Paukku K, Valgeirsdottir S, Saharinen P, Bergman M, Heldin CH, Silvennoinen O. Platelet-derived growth factor (PDGF)-induced activation of signal transducer and activator of transcription (Stat) 5 is mediated by PDGF beta-receptor and is not dependent on c-src, fyn, jak1 or jak2 kinases. Biochem J.2000;345(pt 3): 759-766.","DOI":"10.1042\/bj3450759"},{"key":"2020021217533507900_REF43","doi-asserted-by":"crossref","unstructured":"Chaturvedi P, Reddy MV, Reddy EP. Src kinases and not JAKs activate STATs during IL-3 induced myeloid cell proliferation. Oncogene.1998;16: 1749-1758.","DOI":"10.1038\/sj.onc.1201972"},{"key":"2020021217533507900_REF44","doi-asserted-by":"crossref","unstructured":"Chin H, Arai A, Wakao H, Kamiyama R, Miyasaka N, Miura O. Lyn physically associates with the erythropoietin receptor and may play a role in activation of the Stat5 pathway. Blood.1998;91: 3734-3745.","DOI":"10.1182\/blood.V91.10.3734"},{"key":"2020021217533507900_REF45","doi-asserted-by":"crossref","unstructured":"Olayioye MA, Beuvink I, Horsch K, Daly JM, Hynes NE. ErbB receptor-induced activation of stat transcription factors is mediated by Src tyrosine kinases. J Biol Chem.1999;274: 17209-17218.","DOI":"10.1074\/jbc.274.24.17209"},{"key":"2020021217533507900_REF46","doi-asserted-by":"crossref","unstructured":"Klejman A, Schreiner SJ, Nieborowska-Skorska M, et al. The Src family kinase Hck couples BCR\/ABL to STAT5 activation in myeloid leukemia cells. Embo J.2002;21: 5766-5774.","DOI":"10.1093\/emboj\/cdf562"},{"key":"2020021217533507900_REF47","doi-asserted-by":"crossref","unstructured":"Kovalenko M, Ronnstrand L, Heldin CH, et al. Phosphorylation site-specific inhibition of platelet-derived growth factor beta-receptor autophosphorylation by the receptor blocking tyrphostin AG1296. Biochemistry.1997;36: 6260-6269.","DOI":"10.1021\/bi962553l"},{"key":"2020021217533507900_REF48","doi-asserted-by":"crossref","unstructured":"Yamamoto Y, Kiyoi H, Nakano Y, et al. Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies. Blood.2001;97: 2434-2439.","DOI":"10.1182\/blood.V97.8.2434"},{"key":"2020021217533507900_REF49","doi-asserted-by":"crossref","unstructured":"Levis M, Allebach J, Tse KF, et al. A FLT3-targeted tyrosine kinase inhibitor is cytotoxic to leukemia cells in vitro and in vivo. Blood.2002;99: 3885-3891.","DOI":"10.1182\/blood.V99.11.3885"},{"key":"2020021217533507900_REF50","doi-asserted-by":"crossref","unstructured":"Weisberg E, Boulton C, Kelly LM, et al. Inhibition of mutant FLT3 receptors in leukemia cells by the small molecule tyrosine kinase inhibitor PKC412. Cancer Cell.2002;1: 433-443.","DOI":"10.1016\/S1535-6108(02)00069-7"},{"key":"2020021217533507900_REF51","doi-asserted-by":"crossref","unstructured":"Kelly LM, Yu JC, Boulton CL, et al. CT53518, a novel selective FLT3 antagonist for the treatment of acute myelogenous leukemia (AML). Cancer Cell.2002;1: 421-432.","DOI":"10.1016\/S1535-6108(02)00070-3"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/102\/8\/2969\/1692420\/h82003002969.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/102\/8\/2969\/1692420\/h82003002969.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,26]],"date-time":"2023-04-26T17:00:17Z","timestamp":1682528417000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/102\/8\/2969\/17794\/Different-antiapoptotic-pathways-between-wildtype"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,10,15]]},"references-count":51,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2003,10,15]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2002-12-3813","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2003,10,15]]}}}